Therapeutic synergy and complementarity for ischemia/reperfusion injury: β1-adrenergic blockade and phosphodiesterase-3 inhibition

International Journal of Cardiology

Volumn 214, Issue , 2016, Pages 374-380

  Huang, Ming He ^a,b,c   Poh, Kian Keong ^d   Tan, Huay Cheem ^d   Welt, Frederick G P ^e   Lui, Charles Y ^e  

^a Gulf Coast Heart Clinic (MH)   (United States)

^b ICA Therapeutics   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Epinephrine; ICA cells; Phosphodiesterase 3 inhibitor; Protein kinase A; Reperfusion injury; 1 blocker; 2 adrenergic receptor

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; ESMOLOL; METOPROLOL; MILRINONE; NEUROPEPTIDE RECEPTOR; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PROPANOLAMINE DERIVATIVE;

DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVATION; HEART INFARCTION; HEART PROTECTION; HUMAN; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; MYOCARDIAL REPERFUSION INJURY;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; HUMANS; MYOCARDIAL REPERFUSION INJURY; PHOSPHODIESTERASE 3 INHIBITORS; PROPANOLAMINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84962791574     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.200     Document Type: Review

References (69)

1. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, D.E. Casey, M.K. Chung, J.A. de Lemos, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 61 2013 e48 e140
2. D.S. Menees, E.D. Peterson, Y. Wang, J.P. Curtis, J.C. Messenger, J.S. Rumsfeld, and et al. Door-to-balloon time and mortality among patients undergoing primary PCI N Engl J Med 369 2013 901 909
3. B. Ibanez, G. Heusch, M. Ovize, and F. de Werf Evolving therapies for myocardial ischemia/reperfusion injury (review) J Am Coll Cardiol 65 2015 1454 1471
4. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury (review) N Engl J Med 357 2007 1121 1135
5. D.J. Hausenloy, and D.M. Yellon Myocardial ischemia-reperfusion injury: a neglected therapeutic target (review) J Clin Invest 123 2013 92 100
6. R.A. Gottlieb, K.O. Burleson, R.A. Kloner, B.M. Babior, and R.L. Engler Reperfusion injury induces apoptosis in rabbit cardiomyocytes J Clin Invest 94 1994 1621 1628
7. A. Saraste, K. Pulkki, M. Kallajoki, K. Henriksen, M. Parvinen, and L.-M. Voipio-Pulkki Apoptosis in human acute myocardial infarction Circulation 95 1997 320 323
8. S.B. Ong, P. Samangouei, S.B. Kalkhoran, and D.J. Hausenloy The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury (review) J Mol Cell Cardiol 78 2015 23 34
9. S. Ghaffari, B. Kazemi, M. Toluey, and N. Sepehrvand The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction Cardiovasc Ther 31 2013 e34 e39
10. T.-T. Cung, O. Morel, G. Cayla, G. Rioufol, D. Garcia-Dorado, D. Angoulvant, and et al. Cyclosporine before PCI in patients with acute myocardial infarction N Engl J Med 373 2015 1021 1031
11. F. Ottani, R. Latini, L. Staszewsky, N. Locuratolo, M. Sicuro, S. Masson, and et al. Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial J Am Coll Cardiol 67 2016 365 374
12. The MIAMI Trial Research Group Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo-controlled international trial Eur Heart J 6 1985 199 226
13. ISIS-I (First International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-I Lancet 328 1986 57 66
14. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1622 1632
15. H.J. Geissler, K.L. Davis, L.M. Buja, G.A. Laine, M.L. Brennan, U. Mehlhorn, and et al. Esmolol and cardiopulmonary bypass during reperfusion reduce myocardial infarct size in dogs Ann Thorac Surg 72 2001 1964 1969
16. B. Ibanez, G. Cimminoa, S. Prat-Gonzáleza, G. Vilahur, R. Hutter, M.J. García, and et al. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion Int J Cardiol 147 2011 428 432
17. M.-H. Huang, Y. Wu, V. Nguyen, S. Rastogi, B.K. McConnell, C. Wijaya, and et al. Heart protection by combination therapy with milrinone and esmolol at early reperfusion during acute myocardial infarction Cardiovasc Drugs Ther 25 2011 223 232
18. B. Ibanez, C. Macaya, V. Sánchez-Brunete, G. Pizarro, L. Fernández-Friera, A. Mateos, and et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial Circulation 128 2013 1495 1503
19. G. Pizarro, L. Fernández-Friera, V. Fuster, R. Fernández-Jiménez, J.M. García-Ruiz, A. García-Álvarez, and et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute myocardial infarction) J Am Coll Cardiol 63 2014 2356 2362
20. F. Er, K.M. Dahlem, A.M. Nia, E. Erdmann, J. Waltenberger, M. Hellmich, and et al. Randomized control of sympathetic drive with continuous intravenous esmolol in patients with acute ST-segment elevation myocardial infarction: the BEtA-Blocker therapy in acute myocardial infarction (BEAT-AMI) trial J Am Coll Cardiol Intv 9 2016 231 240
21. M. Esler, G. Eisenhofer, A. Dart, J. Chin, H. Cox, G. Lambert, and et al. Adrenaline release by the human heart Clin Exp Pharmacol Physiol 18 1991 67 70
22. D.M. Kaye, J. Lefkovits, H. Cox, G. Lambert, G. Jennings, A. Turner, and et al. Regional epinephrine kinetics in human heart failure: evidence for extra-adrenal, nonneural release Am J Physiol Heart Circ Physiol 269 1995 H182 H188
23. Y. Kuroko, T. Yamazaki, N. Tokunaga, T. Akiyama, H. Kitagawa, K. Ishino, and et al. Cardiac epinephrine synthesis and ischemia-induced myocardial epinephrine release Cardiovasc Res 74 2007 438 444
24. C.R. Killingsworth, C.C. Wei, L.J. Dell'Italia, J.L. Ardell, M.A. Kingsley, W.M. Smith, and et al. Short-acting beta-adrenergic antagonist esmolol given at reperfusion improves survival after prolonged ventricular fibrillation Circulation 109 2004 2469 2474
25. M.-H. Huang, D.S. Friend, M.E. Sunday, K. Singh, K. Haley, K.F. Austen, and et al. An intrinsic adrenergic system in mammalian heart J Clin Invest 98 1996 1298 1303
26. 2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell Am J Physiol Heart Circ Physiol 293 2007 H376 H384
27. S.N. Ebert, and R.P. Thompson Embryonic epinephrine synthesis in the rat heart before innervations: association with pacemaker and conduction tissue development Circ Res 88 2001 117 124
28. S.N. Ebert, and D.G. Taylor Catecholamines and development of cardiac pacemaking: an intrinsically intimate relationship (review) Cardiovasc Res 72 2006 364 374
29. Y. Tamura, M. Sano, H. Nakamura, K. Ito, Y. Sato, K. Shinmura, and et al. Neural crest-derived resident cardiac cells contribute to the restoration of adrenergic function of transplanted heart in rodent Cardiovasc Res 109 2016 350 357
30. M.-H. Huang, J.J. Bahl, Y. Wu, D.L. Larson, F.L. Hu, and G.A. Ewy Neuroendocrine properties of intrinsic cardiac adrenergic cells in fetal rat heart Am J Physiol Heart Circ Physiol 288 2005 H497 H503
31. 1-receptor down-regulation in heart failure Circ Res 59 1986 297 309
32. M. White, R. Roden, W. Minobe, M.F. Khan, P. Larrabee, M. Wollmering, and et al. Age-related changes in β-adrenergic neuroeffector systems in the human heart Circulation 90 1994 1225 1238
33. 2-adrenergic signaling in adult mouse heart cells Proc Natl Acad Sci U S A 98 2001 1607 1612
34. 2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein Circulation 100 1999 2210 2212
35. H. Tong, D. Bernstein, E. Murphy, and C. Steenbergen The role of β-adrenergic receptor signaling in cardioprotection FASEB J 19 2005 983 985
36. 2-adrenoreceptor stimulation attenuates myocardial cell death and preserves cardiac function after ischemia-reperfusion injury Arterioscler Thromb Vasc Biol 32 2012 1865 1874
37. M.-H. Huang, V. Nguyen, Y. Wu, S. Rastogi, Y. Birnbaum, C.Y. Lui, and et al. Reducing ischemia/reperfusion injury through δ-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signaling Cardiovasc Res 284 2009 452 460
38. 2-adrenergic receptor to different G proteins by protein kinase A Nature 390 1997 88 91
39. A. Bellis, D. Castaldo, V. Trimarco, M.G. Monti, P. Chivasso, J. Sadoshima, and et al. Cross-talk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning Arterioscler Thromb Vasc Biol 29 2009 1207 1212
40. H. Sun, R. Lesche, D.M. Li, J. Liliental, H. Zhang, J. Gao, and et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway Proc Natl Acad Sci U S A 96 1999 6199 6204
41. Q. Zhang, and C.S. Li Combination of epinephrine with esmolol attenuates post-resuscitation myocardial dysfunction in a porcine model of cardiac arrest PLoS One 8 2013 e82677
42. M.G. Rosenfeld, J.-J. Mermod, S.G. Amara, L.W. Swanson, P.E. Sawchenko, J. Rivier, and et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing Nature 304 1983 129 135
43. P. Lechleitner, N. Genser, J. Mair, A. Dienstl, C. Haring, C.T. Wiedermann, and et al. Calcitonin gene-related peptide in patients with and without early reperfusion after acute myocardial infarction Am Heart J 124 1992 1433 1439
44. D.M. Wu, P.A. van Zwieten, and H.N. Doods Effects of calcitonin gene-related peptide and BIBN4096BS on myocardial ischemia in anesthetized rats Acta Pharmacol Sin 22 2001 588 594
45. 2 + mobilization involved in CGRP-mediated positive inotropic effect in ventricular myocytes Am J Physiol 276 1999 R259 R264
46. D. Li, N.S. Li, Q.Q. Chen, R. Guo, P.S. Xu, H.W. Deng, and et al. Calcitonin gene-related peptide-mediated cardioprotection of postconditioning in isolated rat hearts Regul Pept 147 2008 4 8
47. H. Yin, L. Chao, and J. Chao Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling Hypertension 43 2004 109 116
48. 3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation J Am Coll Cardiol 58 2011 2683 2691
49. 3-adrenoceptor agonist in the nonfailing transplanted human heart J Am Coll Cardiol 53 2009 1532 1538
50. 3 Adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes Basic Res Cardiol 109 2014 422 437
51. A. Hovanesyan, and M.W. Rich Outcomes of acute myocardial infarction in nonagenarians Am J Cardiol 101 2008 1378 1383
52. P. Widimsky, Z. Motovská, D. Bílková, M. Aschermann, L. Groch, and M. Zelízko The impact of age and Killip class on outcomes of primary percutaneous coronary intervention. Insight from the PRAGUE-1 and -2 trials and registry EuroIntervention 2 2007 481 486
53. 2-AR-adrenergic responses without changes in inhibitory G proteins or receptor kinases J Clin Invest 101 1998 1273 1282
54. C.P. Hu, J. Peng, L. Xiao, F. Ye, H.W. Deng, and Y.J. Li Effect of age on alpha-calcitonin gene-related peptide-mediated delayed cardioprotection induced by intestinal preconditioning in rats Regul Pept 107 2002 137 143
55. D.J. Hausenloy, and D.M. Yellon Remote ischaemic preconditioning: underlying mechanisms and clinical application (review) Cardiovasc Res 79 2008 377 386
56. S. Sanada, M. Kitakaze, P.J. Papst, H. Asanuma, K. Node, S. Takashima, and et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitor: the role of protein kinases A and p38 mitogen-activated protein kinase Circulation 104 2001 705 710
57. C.A. Campbell, B.R. Reddy, K.J. Alker, J. Wynne, and R.A. Kloner Effect of milrinone on acute myocardial infarct size Am J Cardiol 60 1987 422 443
58. 3A, protects murine heart from ischemia/reperfusion injury Proc Natl Acad Sci U S A 112 2015 E2253 E2262
59. M. Hein, A.B. Roehl, J.H. Baumert, K. Scherer, P. Steendijk, and R. Rossaint Anti-ischemic effects of inotropic agents in experimental right ventricular infarction Acta Anaesthesiol Scand 53 2009 941 948
60. R.P. Karlsberg, M.A. DeWood, A.N. DeMaria, M.R. Berk, and K.P. Lasher Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group Clin Cardiol 19 1996 21 30
61. Z. You, L. Huang, X. Cheng, Q. Wu, X. Jiang, and Y. Wu Effect of milrinone on cardiac functions in patients undergoing coronary artery bypass graft: a meta-analysis of randomized clinical trials Drug Des Dev Ther 10 2016 53 58
62. F. Zoerner, F. Lennmyr, L. Wiklund, C.E. Martijn, and E. Semenas Milrinone and esmolol decrease cardiac damage after resuscitation from prolonged cardiac arrest Acta Anaesthesiol Scand 59 2015 465 474
63. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and M.D. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
64. Y. Ye, K.T. Keys, C. Zhang, J.R. Perez-Polo, Y. Lin, and Y. Birnbaum The myocardial infarct size-limiting effect of stagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA Am J Physiol Heart Circ Physiol 298 2010 H1454 H1465
65. J. Lønborg, N. Vejlstrup, H. Kelbæk, H.E. Bøtker, W.Y. Kim, A.B. Mathiasen, and et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 2012 1491 1499
66. J.S. Woo, W. Kim, S.J. Ha, J.B. Kim, S.-J. Kim, W.-S. Kim, and et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study Arterioscler Thromb Vasc Biol 33 2013 2252 2260
67. J.M. Cruickshank Phosphodiesterase III inhibitors: long-term risks and short-term benefits (review) Cardiovasc Drugs Ther 7 1993 655 660
68. M. Metra, E. Eichhorn, W.T. Abraham, J. Linseman, M. Böhm, R. Corbalan, and et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials Eur Heart J 30 2009 3015 3026
69. K.-K. Poh, X. Xu, W. Sia, M.Y. Chan, A.F. Low, K.H. Chan, and et al. Safety of combination therapy with milrinone and esmolol in heart protection during percutaneous coronary intervention in acute myocardial infarction Eur J Clin Pharmacol 70 2014 527 530